{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-004808","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2025-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.444953+00:00","generated_at":"2026-05-17T23:21:40.055263+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Teva Q2 2025 Non-GAAP EPS $0.66 (+9% YoY); Raises 2025 Innovative Product Revenue Outlook","bullets":["Revenues $4.176B flat YoY; GAAP EPS $0.24; Non-GAAP EPS $0.66 (up from $0.61).","AUSTEDO global revs $498M (+19% LC), AJOVY $155M (+31% LC), UZEDY $54M (+120% YoY).","Raised 2025 revenue outlook: AUSTEDO $2,000-2,050M, AJOVY $630-640M, UZEDY $190-200M.","Non-GAAP operating margin 27.1% (vs 25.3% Q2 2024); adjusted EBITDA $1,233M (+6%).","Free cash flow $476M (+47% YoY); on track for $700M net savings by 2027 from Transformation programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-004808","json":"https://secwatch.observer/filing/0001171843-25-004808.json","markdown":"https://secwatch.observer/filing/0001171843-25-004808.md","text":"https://secwatch.observer/filing/0001171843-25-004808.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000117184325004808/0001171843-25-004808-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000117184325004808/f8k_073025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:21:40.055263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}